 SHANGHAI and SAN FRANCISCO, April 23, 2021 GLOBE NEWSWIRE -- Zai Lab Limited Zai Lab or the Company NASDAQ:ZLAB, HKEX: 9688, an innovative commercial stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,776,000 American depositary shares ADSs, each representing one ordinary share of the Company, at a price of US150.00 per ADS the ADS Offering. Zai Lab had also granted the underwriters a 30-day option to purchase up to an additional 716,400 ADSs at the public offering price, less underwriting discounts and commissions. The underwriters fully exercised their option to purchase these additional ADSs. The ADS Offering closed on April 23, 2021. 